Nail Psoriasis: Clinical Features and Severity Assessment
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
The nail is an important characteristic in the context of psoriasis. Nail psoriasis exhibits sev- eral clinical manifestations. Since the development of the Nail Psoriasis Severity Index (NAPSI) score assessment tool for evaluating the severity of nail psoriasis, nail matrix symptoms such as pitting, leukonychia, crumbling, and red spots have been obser ved in the lunula. Nail bed symptoms include onycholysis, subungual hyperkeratosis, oil spots, and splinter hemorrhage. However, Beau’s lines and nail fold psoriasis, which are not included in this assessment tool, should be considered essential symptoms for indicating the activity of nail psoriasis. Although NAPSI is the most widely used tool for assessing the severity of nail psoriasis, it has uncon- trolled limitations. Although other assessment tools have been developed, none have success- fully replaced the NAPSI. In clinical trials for nail psoriasis, the NAPSI is used in various forms, such as improvement rates, changes in the mean NAPSI score, and achievement rates of NAPSI 75. Consequently, caution is warranted when interpreting the clinical trial results related to nail psoriasis improvement.
Abstract
The nail is an important characteristic in the context of psoriasis. Nail psoriasis exhibits sev- eral clinical manifestations. Since the development of the Nail Psoriasis Severity Index (NAPSI) score assessment tool for evaluating the severity of nail psoriasis, nail matrix symptoms such as pitting, leukonychia, crumbling, and red spots have been obser ved in the lunula. Nail bed symptoms include onycholysis, subungual hyperkeratosis, oil spots, and splinter hemorrhage. However, Beau’s lines and nail fold psoriasis, which are not included in this assessment tool, should be considered essential symptoms for indicating the activity of nail psoriasis. Although NAPSI is the most widely used tool for assessing the severity of nail psoriasis, it has uncon- trolled limitations. Although other assessment tools have been developed, none have success- fully replaced the NAPSI. In clinical trials for nail psoriasis, the NAPSI is used in various forms, such as improvement rates, changes in the mean NAPSI score, and achievement rates of NAPSI 75. Consequently, caution is warranted when interpreting the clinical trial results related to nail psoriasis improvement.
참고문헌 (24)
- Reich K, "Approach to managing patients with nail psoriasis", J Eur Acad Dermatol Venereol, 23(Suppl 1), pp.15~21 (2009)
- Choi JW, "Identification of nail features associated with psoriasis severity", J Dermatol, 44, pp.147~153 (2017)
- Choi JW, "Could psoriatic arthritis be easily diagnosed from current suspicious physical findings in the dermatology clinic?", Ann Dermatol, 29, pp.48~54 (2017)
- Rich P, "Nail Psoriasis Severity Index : a useful tool for evaluation of nail psoriasis", J Am Acad Dermatol, 49, pp.206~212 (2003)
- Kim BR, "Comparison of NAPSI and N-NAIL for evaluation of fingernail psoriasis in patients with moderate-to-severe plaque psoriasis treated using ustekinumab", J Dermatolog Treat, 30, pp.123~128 (2019)
- Cassell SE, "The modified Nail Psoriasis Severity Index : validation of an instrument to assess psoriatic nail involvement in patients with psoriatic arthritis", J Rheumatol, 34, pp.123~129 (2007)
- Byun SY, "Severe nail fold psoriasis extending from nail psoriasis resolved with ustekinumab : suggestion of a cytokine overflow theory in the nail unit", Ann Dermatol, 28, pp.94~97 (2016)
- Kim M, "Nail involvement features in palmoplantar pustulosis", J Dermatol, 48, pp.360~365 (2021)
- Klaassen KM, "The prevalence of onychomycosis in psoriatic patients : a systematic review", J Eur Acad Dermatol Venereol, 28, pp.533~541 (2014)
- Augustin M, "Characterization of patients with psoriatic arthritis in dermatologic and rheumatologic care : analysis of two registries", J Dtsch Dermatol Ges, 21, pp.1170~1176 (2023)
- Baran RL, "A Nail Psoriasis Severity Index", Br J Dermatol, 150, pp.568~569 (2004)
- Klaassen KM, "Scoring nail psoriasis", J Am Acad Dermatol, 70, pp.1061~1066 (2014)
- Rich P, "Ustekinumab improves nail disease in patients with moderate-to-severe psoriasis : results from PHOENIX 1", Br J Dermatol, 170, pp.398~407 (2014)
- Youn SW, "Reduction of inter-rater and intra-rater variability in Psoriasis Area and Severity Index assessment by photographic training", Ann Dermatol, 27, pp.557~562 (2015)
- Choi CW, "Both educational lectures and reference photographs are necessary to improve the accuracy and reliability of Psoriasis Area and Severity Index(PASI)assessment : results from Korean nation-wide PASI educational workshop", Ann Dermatol, 30, pp.284~289 (2018)
- Choi CW, "The objective Psoriasis Area and Severity Index : a randomized controlled pilot study comparing the effectiveness of ciclosporin and methotrexate", Br J Dermatol, 177, pp.1740~1741 (2017)
- Youn SW, "Determination of the Nail Psoriasis Severity Index improvement rate standards for nail psoriasis treatment in a phase IV clinical trial of ustekinumab : the MARCOPOLO study", J Eur Acad Dermatol Venereol, 31, pp.e298~e299 (2017)
- Reich K, "Infliximab induction and maintenance therapy for moderate-to-severe psoriasis : a phase III, multicentre, double-blind trial", Lancet, 366, pp.1367~1374 (2005)
- Poulin Y, "Efficacy of adalimumab across subgroups of patients with moderate-to-severe chronic plaque psoriasis of the hands and", or feet : post hoc analysis of REACH, 2014, pp.28, 882~890
- Huang IH, "Small molecule inhibitors and biologics in treating nail psoriasis : a systematic review and network meta-analysis", J Am Acad Dermatol, 85, pp.135~143 (2021)
- Egeberg A, "Network meta-analyses comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis at 24–28 and 48–52 weeks", J Dermatolog Treat, 34, pp.2263108~ (2023)
- Reich K, "Secukinumab shows high and sustained efficacy in nail psoriasis : 2. 5-year results from the randomized placebo-controlled TRANSFIGURE study", Br J Dermatol, 184, pp.425~436 (2021)
- Chang MJ, "The untold burden of isolated nail psoriasis : delayed diagnosis and significant risk of psoriatic arthritis in a retrospective study at an academic center", J Am Acad Dermatol, 88, pp.1192~1194 (2023)
- Rigopoulos D, "Recommendations for the definition, evaluation, and treatment of nail psoriasis in adult patients with no or mild skin psoriasis : a dermatologist and nail expert group consensus", J Am Acad Dermatol, 81, pp.228~240 (2019)